Mandana Khalili, MD, discusses how baseline motivation predicted alcohol reduction in a stepped treatment trial for liver disease patients.
Mandana Khalili, MD
Advertisement
Mandana Khalili, MD, is Chief of Clinical Hepatology and Director of Clinical and Translational Research in Hepatology at San Francisco General Hospital, and directs the UCSF T32 Hepatology Training Program.
Articles by Mandana Khalili, MD
Telehealth stepped alcohol treatment reduced weekly drinking, but not the primary endpoint, among patients with chronic liver disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Alpha-Gal Syndrome: Closing an Underrecognized Allergy Diagnostic Gap
2
Pelacarsen Misses Primary Endpoint in Lp(a)HORIZON Phase 3 Trial
3
GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF
4
ORFAN-MAESTRIA: AI Predicts Cardioembolic Stroke, Atrial Fibrillation from CT Scans
5